BSX - Boston Scientific Corporation

NYSE - NYSE Delayed Price. Currency in USD
44.28
+1.08 (+2.50%)
At close: 4:01PM EST
Stock chart is not supported by your current browser
Previous Close43.20
Open43.20
Bid44.00 x 800
Ask44.28 x 3200
Day's Range43.14 - 44.31
52 Week Range34.35 - 46.62
Volume15,417,119
Avg. Volume6,883,369
Market Cap61.718B
Beta (5Y Monthly)0.79
PE Ratio (TTM)57.51
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • Boston Scientific Announces Preliminary Unaudited Sales For The Fourth Quarter And Full Year 2019
    PR Newswire

    Boston Scientific Announces Preliminary Unaudited Sales For The Fourth Quarter And Full Year 2019

    Boston Scientific Corporation (NYSE: BSX) generated sales, based upon preliminary unaudited financial information, of approximately $2.90 billion during the fourth quarter of 2019. This represents growth of approximately 13.4 percent on a reported basis, compared to the company's guidance range of 13 to 15 percent; approximately 14.1 percent on an operational1 basis, compared to the company's guidance range of 14 to 16 percent; and approximately 7.3 percent on an organic2 basis, compared to the company's guidance range of 8 to 9 percent, all compared to the prior year period.

  • Boston Scientific Announces January Conference Schedule and Conference Call Discussing Fourth Quarter 2019 Results
    PR Newswire

    Boston Scientific Announces January Conference Schedule and Conference Call Discussing Fourth Quarter 2019 Results

    Boston Scientific Corporation (NYSE: BSX) will participate in the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020 in San Francisco, California. Mike Mahoney, chairman and chief executive officer, will present at approximately 8:00 a.m. PST / 11:00 a.m. EST. At 8:30 a.m. PST / 11:30 a.m. EST, Mahoney will be joined by Dan Brennan, executive vice president and chief financial officer, Ian Meredith, MD, executive vice president and global chief medical officer, and Susie Lisa, vice president, Investor Relations, in a question-and-answer session with the host analyst and audience members.

  • Boston Scientific Receives FDA Clearance For World's First Single-Use Duodenoscope, EXALT™ Model D
    PR Newswire

    Boston Scientific Receives FDA Clearance For World's First Single-Use Duodenoscope, EXALT™ Model D

    Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the EXALT™ Model D Single-Use Duodenoscope for use in endoscopic retrograde cholangiopancreatography (ERCP) procedures. The EXALT Model D Duodenoscope is the first and only FDA cleared single-use (disposable) duodenoscope on the market and was granted Breakthrough Device Designation from the FDA to ensure patients and healthcare providers have timely access to this device.

  • Boston Scientific to Participate in Evercore ISI and Piper Jaffray Healthcare Conferences
    PR Newswire

    Boston Scientific to Participate in Evercore ISI and Piper Jaffray Healthcare Conferences

    MARLBOROUGH, Mass. , Nov. 21, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in two investor conferences this December. On Wednesday, December 4, 2019 , Susie ...

  • Boston Scientific Completes €900 million Offering of Senior Notes and $1.0 billion Tender Offer
    PR Newswire

    Boston Scientific Completes €900 million Offering of Senior Notes and $1.0 billion Tender Offer

    MARLBOROUGH, Mass. , Nov. 12, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) (the "Company") completed a public offering of €900.0 million aggregate principal amount of 0.625% ...

  • PR Newswire

    Boston Scientific Prices €900,000,000 of Senior Notes

    MARLBOROUGH, Mass., Nov. 6, 2019 /PRNewswire/ -- Boston Scientific Corporation (the "Company") (BSX) announced the pricing of a public offering of €900,000,000 aggregate principal amount of its 0.625% notes due 2027, under the Company's shelf registration statement. The Company expects to receive the net offering proceeds upon closing on November 12, 2019, subject to customary closing conditions. The Company intends to use the net proceeds from the offering to (i) fund the previously announced tender offer for up to $1.0 billion in aggregate principal amount of certain series of the Company's senior notes (the "Tender Offer") and (ii) pay accrued and unpaid interest, premiums, fees and expenses in connection with the Tender Offer.

  • PR Newswire

    Boston Scientific Announces Pricing Terms of Its Cash Tender Offer for up to $1.0 Billion of Its Outstanding Debt Securities

    MARLBOROUGH, Mass., Nov. 5, 2019 /PRNewswire/ -- Boston Scientific Corporation (the "Company") (BSX) today announced the pricing terms of the previously announced cash tender offer (the "Tender Offer") for up to $1.0 billion aggregate principal amount (the "Aggregate Maximum Principal Amount") of the outstanding senior notes listed in the table below (the "Securities"). The table below summarizes certain information regarding the Securities and the Tender Offer, including the order of priority and purchase price information for the Securities.

  • PR Newswire

    Boston Scientific Announces Positive Data for the Ranger™ Drug-Coated Balloon and the Eluvia™ Drug-Eluting Vascular Stent at VIVA19

    LAS VEGAS and MARLBOROUGH, Mass., Nov. 5, 2019 /PRNewswire/ -- Today, Boston Scientific (BSX) announced positive data for two devices within the peripheral drug-eluting product portfolio during separate late-breaking clinical trial presentations at Vascular InterVentional Advances (VIVA) meeting in Las Vegas. The RANGER II SFA study evaluated the safety and effectiveness of the Ranger DCB, which has a low drug dose density of paclitaxel, versus standard percutaneous transluminal angioplasty (PTA) for the treatment of patients with peripheral artery disease (PAD) in the superficial femoral artery (SFA) and proximal popliteal artery (PPA).

  • Boston Scientific Announces Early Results of Its Cash Tender Offer for up to $1.0 Billion of Its Outstanding Debt Securities
    PR Newswire

    Boston Scientific Announces Early Results of Its Cash Tender Offer for up to $1.0 Billion of Its Outstanding Debt Securities

    MARLBOROUGH, Mass., Nov. 5, 2019 /PRNewswire/ -- Boston Scientific Corporation (the "Company") (BSX) today announced that, pursuant to the previously announced cash tender offer (the "Tender Offer") for up to $1.0 billion aggregate principal amount (the "Aggregate Maximum Principal Amount") of the outstanding senior notes listed in the table below (the "Securities"), approximately $1.6 billion in aggregate principal amount of the Securities were validly tendered and not validly withdrawn on or prior to 5:00 p.m., Eastern Standard Time (EST), on November 4, 2019 (the "Early Tender Date"). Withdrawal rights for the Tender Offer expired at 5:00 p.m. EST on November 4, 2019, and, accordingly, Securities validly tendered in the Tender Offer may no longer be withdrawn except where additional withdrawal rights are required by law.

  • Boston Scientific Announces November 2019 Conference Schedule
    PR Newswire

    Boston Scientific Announces November 2019 Conference Schedule

    MARLBOROUGH, Mass. , Nov. 1, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in four conferences, including one industry conference and three investor conferences, this ...

  • Boston Scientific Announces Results For Third Quarter 2019
    PR Newswire

    Boston Scientific Announces Results For Third Quarter 2019

    MARLBOROUGH, Mass. , Oct. 23, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated sales of $2.707 billion during the third quarter of 2019. This represents growth of 13.1 percent on ...

  • Boston Scientific Announces Cash Tender Offer for Up To $1.0 Billion of Its Outstanding Debt Securities
    PR Newswire

    Boston Scientific Announces Cash Tender Offer for Up To $1.0 Billion of Its Outstanding Debt Securities

    MARLBOROUGH, Mass., Oct. 22, 2019 /PRNewswire/ -- Boston Scientific Corporation (the "Company") (BSX) today announced the commencement of a cash tender offer (the "Tender Offer") for up to $1.0 billion aggregate principal amount (the "Aggregate Maximum Principal Amount") of the outstanding senior notes listed in the table below (the "Securities"). The table below summarizes certain information regarding the Securities and the Tender Offer, including the order of priority and purchase price information for the Securities.

  • Boston Scientific Announces Conference Call Discussing Third Quarter 2019 Financial Results
    PR Newswire

    Boston Scientific Announces Conference Call Discussing Third Quarter 2019 Financial Results

    MARLBOROUGH, Mass. , Oct. 1, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended ...

  • PR Newswire

    Boston Scientific Announces Positive Data from the EVOLVE Short DAPT study with the SYNERGY™ Bioabsorbable Polymer Stent

    SAN FRANCISCO and MARLBOROUGH, Mass., Sept. 26, 2019 /PRNewswire/ -- Boston Scientific (BSX) has announced primary endpoint results from the EVOLVE Short DAPT clinical trial, the first prospective study initiated in the U.S. to examine the safety of a shortened duration of dual antiplatelet therapy (DAPT) in patients at high risk for bleeding. Results were presented during a late-breaking clinical science session at the 31st Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, in San Francisco, and demonstrated that a three-month regimen of DAPT is non-inferior to a 12-month or longer regimen in patients with an increased risk of bleeding after being treated with the SYNERGY™ Bioabsorbable Polymer (BP) Stent.

  • PR Newswire

    Boston Scientific Announces Scheduled Presentations at Transcatheter Cardiovascular Therapeutics 2019

    MARLBOROUGH, Mass. , Sept. 18, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced key data that will be presented at the 31st Transcatheter Cardiovascular Therapeutics (TCT), ...

  • Boston Scientific to Participate in the 2019 Wells Fargo Securities Healthcare Conference
    PR Newswire

    Boston Scientific to Participate in the 2019 Wells Fargo Securities Healthcare Conference

    MARLBOROUGH, Mass. , Aug. 20, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2019 Wells Fargo Securities Healthcare Conference on Thursday, September ...

  • Boston Scientific Announces FDA Approval Of ImageReady™ MRI For Vercise Gevia™ Deep Brain Stimulation System
    PR Newswire

    Boston Scientific Announces FDA Approval Of ImageReady™ MRI For Vercise Gevia™ Deep Brain Stimulation System

    MARLBOROUGH, Mass., Aug. 19, 2019 /PRNewswire/ -- Boston Scientific Corporation (BSX) announced the U.S. Food and Drug Administration (FDA) approval of its ImageReady™ MRI labeling for the Vercise Gevia™  Deep Brain Stimulation (DBS) System to be used in a full-body magnetic resonance imaging (MRI) environment.1  This system, with the Vercise Cartesia™ Directional Lead, is designed to treat the symptoms of Parkinson's Disease (PD) by delivering precisely targeted electrical stimulation in the brain to provide optimal symptom relief and better control of unwanted side effects.

  • PR Newswire

    Boston Scientific Closes Acquisition of BTG plc.

    MARLBOROUGH, Mass., Aug. 19, 2019 /PRNewswire/ -- Boston Scientific Corporation (BSX) today announced the completion of its acquisition of BTG plc. (BTG.L) pursuant to the previously announced scheme of arrangement. BTG has three key businesses, the largest of which is its highly-differentiated Interventional Medicine portfolio that encompasses interventional oncology therapeutic technologies for patients with liver and kidney cancers, as well as a vascular portfolio for treatment of deep vein thrombosis, pulmonary embolism, deep venous obstruction and superficial venous disease. "The addition of the BTG Interventional Medicine portfolio reinforces our category leadership strategy and enables us to offer best-in-class technologies, unparalleled clinical evidence and a strengthened commercial infrastructure to support physicians treating some of the most challenging diseases impacting patient health around the world," said Mike Mahoney, chairman and chief executive officer, Boston Scientific.

  • Boston Scientific to Participate in 39th Annual Canaccord Genuity Growth Conference
    PR Newswire

    Boston Scientific to Participate in 39th Annual Canaccord Genuity Growth Conference

    MARLBOROUGH, Mass. , July 25, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in the 39 th Annual Canaccord Genuity Growth Conference on Thursday, August 8, 2019 in Boston ...

  • Boston Scientific Announces Results For Second Quarter 2019
    PR Newswire

    Boston Scientific Announces Results For Second Quarter 2019

    MARLBOROUGH, Mass. , July 24, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated sales of $2.631 billion during the second quarter of 2019. This represents growth of 5.6 percent on ...

  • Boston Scientific Announces Conference Call Discussing Second Quarter 2019 Financial Results
    PR Newswire

    Boston Scientific Announces Conference Call Discussing Second Quarter 2019 Financial Results

    MARLBOROUGH, Mass. , July 1, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ...

  • Saluda Medical Raises $75 Million Equity Financing from Boston Scientific and Redmile Group
    PR Newswire

    Saluda Medical Raises $75 Million Equity Financing from Boston Scientific and Redmile Group

    ARTARMON, Australia , June 28, 2019 /PRNewswire/ -- Saluda Medical Pty Limited ("Saluda Medical") today announced that it has secured $75 million in equity financing from Boston Scientific Corporation ...

  • Boston Scientific Presents Strategies for Sustained Long-Range Growth Targets at 2019 Investor Day
    PR Newswire

    Boston Scientific Presents Strategies for Sustained Long-Range Growth Targets at 2019 Investor Day

    MARLBOROUGH, Mass., June 26, 2019 /PRNewswire/ -- Boston Scientific Corporation (BSX) is hosting a meeting with the investment community today in New York City to review its business and long-term growth strategies. The company is presenting plans for its product pipeline and strategic investments to enable improved clinical and economic outcomes, sustain category leadership in served markets and expand into high-growth, adjacent markets to deliver strong financial performance across the company's MedSurg, Rhythm and Neuro, and Cardiovascular segments. "This is an exciting time for Boston Scientific to help more patients live better and longer lives through the benefits provided by our current medical devices and treatment therapies, while we invest in and develop a robust, long-term pipeline of future technologies," said Mike Mahoney, chairman and chief executive officer, Boston Scientific.

  • ACCESSWIRE

    FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of BSX, HRTX and BOX

    CEDARHURST, NEW YORK / ACCESSWIRE / June 24, 2019 / The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are encouraged to contact the firm regarding possible appointment as lead plaintiff and a preliminary estimate of their recoverable losses. If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court.

  • GlobeNewswire

    DEADLINE MONDAY ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Boston Scientific Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Boston Scientific Corporation (“Boston Scientific” or “the Company”) (NYSE: BSX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.